| 摘要 |
Disclosed is the use of at least one peptide consisting of the amino acid sequence GGL, GLG, LGL, LLG, LGG, GLL, GGdL, GdLG, GdLL, GLdL, GdLdL, dLLG, LdLG, dLdLG, dLGG, dLGL, LGdL or LGdL or a pharmaceutically acceptable salt of the peptide, in the manufacture of a medicament for the treatment of a condition selected from prediabetes, diabetes, obesity, high blood pressure, metabolic syndrome, poor glycemic control, or reduced insulin secretion or for the treatment of a complication associated with diabetes. |
